VR Logo

SELLAS Life Sciences Group Inc. (SLS) download report


Healthcare | Biotechnology & Pharma Research

SELLAS Life Sciences Group Inc. (SLS) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.

IPO Date: 29-Dec-2017

Founder, Pres, CEO & Director: Dr. Angelos M. Stergiou M.D., ScD h.c.

Exec. VP, Gen. Counsel & Sec.: Ms. Barbara A. Wood

Listing: NASDAQ: SLS

Country: United States

Headquarters: New York, NY

Website: https://www.sellaslifesciences.com

Key Facts

Market cap: $46.41 Mln

Revenue (TTM): $2.90 Mln

Earnings (TTM): $-35.04 Mln

Cash: $14.25 Mln

Total Debt: $1.21 Mln

Insider's Holding: 0.09%

Liquidity: Low

52 Week range: $2.10 - 10.82

Shares outstanding: 20,535,600

10 Years Aggregate:

  • CFO: $-255.31 Mln
  • EBITDA: $-305.83 Mln
  • Net Profit: $-327.14 Mln

Stock Performance

Time Period SELLAS Life Sciences Group (SLS) S&P BSE Sensex S&P Small-Cap 600
YTD-60.22-9.18-18.78
1 month-25.68-4.78-8.00
3 months-67.07-9.66-13.65
1 Year-80.180.81-17.19
3 Years-26.8710.336.10
5 Years-69.7711.345.87
10 Years-63.2911.749.84
As on 01-Jul-2022
Year SELLAS Life Sciences Group (SLS) S&P Small-Cap 600 S&P BSE Sensex
2021-4.8225.2721.99
202035.129.5715.75
2019-93.0120.8614.38
2018-84.19-9.705.87
2017-86.4911.7327.91
2016-93.4024.741.95
2015-2.65-3.36-5.03